References
- Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350.
- Eichler H-G, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495–506.
- FDA. Guidance for industry: in vitro companion diagnostic devices. Silverspring (MD): FDA; 2014.
- PharmGKB. Internetquelle [cited 2016 May]. Available from: https://www.pharmgkb.org/view/drug-labels.do.
- Shah RR, Gaedigk A, Llerena A, et al. CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics. 2016;17(3):259–275.
- Stingl JC, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18(3):273–287.
- Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257–265.
- Wang J, Sönnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16(3):191–198.
- Swart M, Skelton M, Ren Y, et al. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics. 2013;23(8):415–427.
- Best MG, Sol N, Kooi I, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28(5):666–676.
- Leyens L, Richer É, Melien Ø, et al. Available tools to facilitate early patient access to medicines in the EU and the USA: analysis of conditional approvals and the implications for personalized medicine. Public Health Genomics. 2015;18(5):249–259.
- EuropeanCommission. Directive 98/79/EC on IVD medical devices (IVDD) (10/1998). Bruxelles (Belgium): European Commisssion; 1998.
- FDA. Guidance for industry: biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions. Silverspring (MD): FDA; 2011.
- EMA. Qualification of novel methodologies for drug development: guidance to applicants. London: EMA; 2014.
- Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–467.